Although speculation continues over when the Federal Reserve will hike interest rates, investors seem to have brushed aside concerns over a rate hike...
Keep Reading →
September 12 - Market Movers, News - Comments
The rumor mill is working hard right now in the biotech space, and the latest word is that Retrophin Inc (NASDAQ:RTRX), the company founded by Martin...
Keep Reading →
August 22 - News, Stock Analysis - Comments
The US stock market is mixed on Thursday with S&P 500 and NASDAQ Composite trading up by 0.09% and 0.17%, respectively, while Dow Jones has inched...
Keep Reading →
August 18 - Earnings Report, News - Comments
Kevin Kotler‘s healthcare-focused fund Broadfin Capital held a 13F portfolio valued at about $1.04 billion at the end of the first quarter, according...
Keep Reading →
June 11 - Hedge Funds, News - Comments
Although the average hedge fund has been struggling to beat broader market benchmarks in recent years, the hedge fund industry as a whole has been constantly...
Keep Reading →
January 29 - Hedge Funds, News - Comments
Among the largest decliners today are Sonic Corporation (NASDAQ:SONC), down by a little over 8%, CONN’s, Inc. (NASDAQ:CONN), slipping by just...
Keep Reading →
September 15 - Hedge Funds, Market Movers, News - Comments
Three healthcare stocks have been very active during both the pre-market and morning trading sessions today. Raptor Pharmaceutical Corp. (NASDAQ:RPTP)...
Keep Reading →
September 14 - Hedge Funds, Market Movers, News - Comments
Following a downgrade from Oppenheimer analyst Christopher Marai, Raptor Pharmaceutical Corp. (NASDAQ:RPTP)‘s stock fell by more than 12% on Monday...
Keep Reading →
July 8 - Market Movers, News - Comments
What’s a smart Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) investor to do? In the 21st century investor’s toolkit, there are dozens of indicators...
Keep Reading →
September 17 - News - Comments
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur. The best way to protect yourself is to be logical when...
Keep Reading →
September 16 - News - Comments
Orphan drug status, which is given to drugs meant for the treatment of rare diseases, offers drug developers a path to faster approval and enhanced market...
Keep Reading →
September 6 - News - Comments
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called “Better Know a District,” which highlights...
Keep Reading →
August 20 - News - Comments
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations...
Keep Reading →
July 19 - News - Comments
Orphan drug companies are an exciting new class in the healthcare sector — with good and bad investment opportunities — let’s look at...
Keep Reading →
June 28 - News - Comments
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) signed an agreement with HealthCare Royalty Partners. On the face, this deal looks good for shareholders injecting...
Keep Reading →
June 17 - News - Comments
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) was in 16 hedge funds’ portfolio at the end of March. ASTX investors should be aware of an increase in...
Keep Reading →
June 12 - News - Comments
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Keep Reading →
May 4 - News - Comments
Last week we focused on five can’t-miss earnings reports. This week, we’re going to turn the tables back to the Food and Drug Administration...
Keep Reading →
April 29 - News - Comments
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical...
Keep Reading →
April 24 - News - Comments
